Novavax Inc Stock Price, News & Analysis

Novavax (NASDAQ:NVAX) has received FDA approval for its Nuvaxovid™ 2025-2026 Formula, the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. The vaccine is approved for adults aged 65 and older and individuals 12-64 years with high-risk conditions.

Clinical and preclinical data demonstrate the vaccine's effectiveness against currently circulating JN.1 lineage strains, including NB.1.8.1, LP.8.1, XFG, XFC, LF.7, and XEC. Sanofi will lead commercialization efforts, with Novavax receiving tiered royalties from vaccine sales.

The vaccine's safety profile includes warnings for potential side effects such as myocarditis, pericarditis, and common reactions like injection site tenderness and fatigue.

Novavax (NASDAQ:NVAX) has announced a significant debt refinancing transaction involving its convertible notes. The company will issue $225 million of 4.625% Convertible Senior Notes due 2031, comprising $175.3 million in exchange for existing 2027 Notes and $49.7 million in new funding.

The 2031 Notes will have an initial conversion price of $11.14 per share, representing a 27.5% premium over the August 20, 2025 closing price. After the transaction's completion, expected around August 27, 2025, $26.5 million of the 2027 Notes will remain outstanding, while the new 2031 Notes will total $225 million.

Novavax (NASDAQ:NVAX) reported second quarter 2025 financial results with total revenue of $239 million, down 42% from $415 million in Q2 2024. Key highlights include FDA BLA approval for Nuvaxovid™, triggering a $175 million milestone payment from Sanofi, and completion of the U.S. commercial leadership transition to Sanofi for the 2025-2026 COVID-19 vaccination season.

The company reported net income of $107 million and ended the quarter with $628 million in cash. Phase 3 trial data for COVID-19-Influenza-Combination and stand-alone influenza vaccine candidates showed robust immune responses. Novavax updated its Full Year 2025 guidance, expecting Adjusted Total Revenue between $1,000-$1,050 million and combined R&D and SG&A expenses of $495-$545 million.

Novavax (Nasdaq: NVAX) has scheduled its second quarter 2025 financial results and operational highlights conference call for August 6, 2025, at 8:30 a.m. ET. The company will host a conference call with both domestic and international dial-in options, and participants can register online for automated callback access.

A replay of the conference call will be available from 11:30 a.m. ET on August 6 until August 13, 2025. The webcast replay will remain accessible on the company's investor relations website until September 5, 2025.

Novavax (NASDAQ:NVAX) has announced promising preclinical data for its H5N1 avian pandemic influenza vaccine candidate, published in Nature Communications. The vaccine, utilizing Novavax's recombinant protein-based nanoparticle technology and Matrix-M® adjuvant, demonstrated strong immune responses in nonhuman primates through both intranasal and intramuscular administration.

The study revealed that a single dose induced significant neutralizing antibody responses (intranasal: 1:54; intramuscular: 1:1,160), exceeding the protective threshold of 1:40 titer. The vaccine showed potential effectiveness against forward-drift variants of currently circulating H5N1 strains. Novavax plans to pursue funding, partnership, and licensing opportunities for this vaccine candidate as part of its corporate growth strategy.

Novavax (NVAX) announced positive results from the initial cohort of its Phase 3 trial evaluating both its COVID-19-Influenza Combination (CIC) and standalone trivalent influenza (tNIV) vaccine candidates. The trial, conducted in adults aged 65 and older, demonstrated robust immune responses for both vaccines compared to licensed products Nuvaxovid and Fluzone HD. The vaccines showed 2.4-5.7-fold increase in immune response over baseline across all tested antigens. Safety profiles were favorable with over 98% of solicited adverse events being mild or moderate. The descriptive trial involved approximately 2,000 participants and was designed to inform future registrational Phase 3 programs. Novavax is actively seeking partnership opportunities to advance these vaccine programs further.

Novavax (NASDAQ: NVAX) has announced its participation in two major upcoming investor conferences in June 2025. The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, from 2:00-2:30 PM ET in New York. Additionally, Novavax will deliver a presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, from 2:00-2:35 PM ET in Miami Beach.

Both events will be webcasted and available on Novavax's investor relations website at ir.novavax.com, with replays accessible for 30 days following the events.

The FDA has approved Novavax's (NVAX) Biologics License Application for Nuvaxovid™, its COVID-19 vaccine. The approval is for adults 65+ and individuals 12-64 with high-risk conditions. This triggers a $175 million milestone payment from Sanofi under their May 2024 collaboration agreement, which includes future tiered royalties. Nuvaxovid is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S. The FDA has requested a new Phase 4 trial for individuals 50-64 without high-risk conditions. Novavax plans to deliver the 2025-2026 COVID-19 vaccine formula this fall through Sanofi, pending strain recommendations. The vaccine has been available under Emergency Use Authorization since July 2022 and has full market approvals in multiple countries.

Novavax (NVAX) reported strong Q1 2025 financial results with total revenue of $667 million, compared to $94 million in Q1 2024. The company posted a net income of $519 million, a significant improvement from a net loss of $148 million in the same period last year. Key highlights include: • Raised 2025 revenue guidance to $975-$1,025 million • Received positive FDA feedback on COVID-19 BLA, with potential $175 million milestone payment upon approval • SHIELD-Utah study showed Nuvaxovid had 39% fewer reactogenicity symptoms vs mRNA vaccine • Strengthened partnership with Takeda in Japan, including $20 million upfront payment • Maintained 2025 guidance for R&D and SG&A expenses at $475-$525 million The company continues to advance its three strategic priorities: optimizing Sanofi partnership, developing new partnerships, and advancing early-stage pipeline development.